微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
RSS 官方收录 · 可信分层展示
关键摘要
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
摘要引擎：抽取
正文提要
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.